ECM
CPRX

Everence Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Everence Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,260
Closed -$303K – 864
2024
Q3 		$303K Hold
15,260
– – 0.02% 583
2024
Q2 		$230 Hold
15,260
– – 0.02% 635
2024
Q1 		$243 Hold
15,260
– – 0.02% 644
2023
Q4 		$257K Hold
15,260
– – 0.02% 605
2023
Q3 		$178 Hold
15,260
– – 0.01% 695
2023
Q2 		$176K Hold
15,260
– – 0.01% 670
2023
Q1 		$253 Sell
15,260
-1,860
-11% -$30.7K 0.02% 600
2022
Q4 		$318 Hold
17,120
– – 0.03% 520
2022
Q3 		$220K Buy
+17,120
New +$203K 0.02% 619

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Everence Capital Management's CPRX Position: Q4 2024 in Review

Everence Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2024, closing a stake of 15,260 shares — an estimated $303K sold.

Everence Capital Management first reported a position in CPRX in Q3 2022 and held it in 9 quarters. The position peaked at $303K in Q3 2024. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

  • Everence Capital Management reported no remaining Catalyst Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Everence Capital Management sold 15,260 Catalyst Pharmaceutical shares in Q4 2024, an estimated $303K.
  • Everence Capital Management first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 9 quarters.
  • Everence Capital Management's Catalyst Pharmaceutical position peaked at $303K in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on Everence Capital Management's 13F filing for Q4 2024, filed 3 Jan 2025.